AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease. The study is designed to assess the safety, tolerability, pharmacokinetics and lipid effects of ACP-501. The trial will be conducted by the National Institute of Health (NIH) and Robert D. Shamburek, MD, will serve as the principal investigator of the study.
"We are happy to announce the initiation of this single-dose tolerance study. This marks a significant milestone in the development of ACP-501. We are pleased to be collaborating with the NIH on this important clinical study," stated Bruce Auerbach, President of AlphaCore Pharma.
ACP-501 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has demonstrated preclinical efficacy in promoting HDL maturation and cholesterol flux, natural cardioprotective mechanisms by which excess lipids are removed from peripheral tissues. The program has an eventual goal to reduce the risk of cardiovascular events in patients presenting with acute coronary syndromes.